Protective Effects of Jasonia Montana-Selenium Nanoparticles Against Doxorubicin-Induced Liver Toxicity
Authors
- Mona S. Abd El-Latif Shaban Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Dina A. Yousif Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Nada A. Ahmed Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Gehad R. Abd Allah Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Yasmen A. Elbagoury Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Nour E. El Sayed Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Hossam A. Hassan Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Bassem M. El-hefnawy Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Ahmed R. Nageh Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- El-Sayed S. Amer Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Ahmed H. Mohamed Department of Radiology and Medical Imaging, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
- Naglaa A. Gobba Department of Pharmacology, Faculty of Pharmacy, MUST University, October 6th City, Egypt
-
Mohammed A. Hussein
Department of Biochemistry, Faculty of Applied Medical Science, October 6th University, October 6th City, Egypt
DOI:
https://doi.org/10.3923/pjn.2021.37.45Keywords:
Caspase-8, doxorubicin, IL-1β, Jasonia Montana, liver toxicity, selenium nanoparticles, TNF- κBAbstract
Background and Objective: Doxorubicin administration induces hepatotoxicity by production of reactive oxygen species (ROS) and cytokines that result in imbalanced redox potential leading to oxidative stress and reduced levels of antioxidant enzymes. The purpose of this study was to evaluate the protective effect of Jasonia Montana aqueous extract-selenium Nanoparticles (JMAE-SeNPs) against Dox-induced liver toxicity in rats. Materials and Methods: JMAE-SeNPs were prepared and characterized in terms of particle size and zeta potential. Furthermore, the IC50 of JMAE-SeNPs against Hep-G2 liver carcinoma cell line and LD50 was calculated. A total of 84 adult albino rats were used to assess the liver protective activity of JMAE-SeNPs against DOX-induced liver toxicity in rats. Results: JMAE-SeNPs had size of around 25 nm with negative zeta potential of -36.8±0.62. Also, its IC50 against Hep-G2 liver carcinoma cell line and LD50 was equal to 166.78 μg mL–1 and 1120 mg kg–1 body weight, respectively. The daily oral administration of JMAE-SeNPs at concentrations of 1/50 LD50 (25 mg kg–1 body weight) and 1/20 LD50 (50 mg kg–1 body weight) for 30 days to rats treated with DOX (2.0 mg kg–1 body weight) resulted in a significant improvement in plasma ALT, AST, AST and LDH as well as liver MDA, caspase-8, TNF- κB and IL-1β. Oral administration of JMAE-SeNPs, on the other hand, increased the activity of SOD, GPx and GSH in DOX-treated rats. Furthermore, JMAE-SeNPs almost normalized these effects of DOX in liver tissue. Conclusion: The biochemical and histological findings of our study demonstrated that JMAE-SeNPs have liver protective activity against DOX-induced liver toxicity in rats.
References
Fulbright, J.M., 2011. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol. Res. Pract., Vol. 2011.
Feola, M., O. Garrone, M. Occelli, A. Francini and A. Biggi et al., 2011. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int. J. Cardiol., 148: 194-198.
Dudka, J., F. Burdan, A. Korga, K. Dyndor and I. Syroka, 2009. The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig Med Dosw, 7: 225-233.
Grenier, M.A. and S.E. Lipshultz, 1998. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol., 24: 72-85.
Steinherz, L.J., P.G. Steinherz, C.T. Tan, G. Heller, M.L. Murphy, 1991. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J. Am. Med. Assoc., 266: 1672-1677.
Minotti, G., P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, 2004. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 56: 185-229.
Korga, A., J. Dudka, F. Burdan, J. Sliwinska, S. Mandziuk and K. Dawidek-Pietryka, 2012. The redox imbalance and the reduction of contractile protein content in rat hearts administered with l-thyroxine and doxorubicin. Oxidative Med. Cell. Longevity, Vol. 2012.
Xu, M.F., P.L. Tang, Z.M. Qian and M. Ashraf, 2001. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci., 68: 889-901.
Doroshow, J.H., 1983. Effect of anthracycline antibiotics on oxygen radicals formation in rat heart. Cancer Res., 43: 460-472.
Bachur, N.R., S.L. Gordon and M.V. Gee, 1978. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res., 38: 1745-1750.
Vásquez-Vivar, J., P. Martasek, N. Hogg, B.S.S. Masters, K.A. Pritchard, and B. Kalyanaraman, 1997. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry, 36: 11293-11297.
Mansour, M.A., A.G. El-Din, M.N. Nagi, O.A. Al-Shabanah and A.M. Al-Bekairi, 2003. Nω-nitro-Ll-arginine methylester ameliorates myocardial toxicity induced by doxorubicin. J. Biochem. Mol. Biol., 36: 593-596.
Nithipongvanitch, R., W. Ittarat, M.P. Cole, J. Tangpong, D.K. Clair and T.D. Oberley, 2007. Mitochondrial and nuclear p53 localization in cardiomyocytes: Redox modulation by doxorubicin (Adriamycin)?. Antioxid. Redox Signal, 9: 1001-1008.
Zhao, Y., D. McLaughlin, E. Robinson, A.P. Harvey and M.B. Hookham et al., 2010. Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy. Cancer Res., 70: 9287-9297.
Deng, S., A. Kruger, A. Kleschyov, L. Kalinowski, A. Daiber and L. Wojnowski, 2007. Gp91phox-containing NAD(P)H oxidase increases superoxide formation by doxorubicin and NADPH. Free Radical Biol. Med., 42: 466-473.
Yee, S.B. and C.A. Pritsos, 1997. Comparison of oxygen radical generation from the reductive activation of doxorubicin, streptonigrin, and menadione by xanthine oxidase and xanthine dehydrogenase. Arch. Biochem. Biophys., 347: 235-241.
Heywood, V.H., 1977. The Biology and Chemistry of Compositae. Academic Press, London, pp: 1-11.
Täckholm, V., 1974. Students’ Flora of Egypt. 2nd Edn., Cairo University Publishing, Beirut, Lebanon, Pages: 888.
Hussein, M.A. and H.S. Farghaly, 2010. Protective effects of Jasonia Montana against lipid peroxidation in liver and kidney of iron-overloaded rats. Aust. J. Basic Applied Sci., 4: 2004-2012.
Dugda, M.T., 2005. Crustal structure in Ethiopia and Kenya from receiver function analysis: implications for rift development in eastern Africa. J. Geophys. Res., Vol. 110.
Ahmed, A.A., J. Jakupovic and A. Ali, 1988. 11-Hydroxyjasionone, a new sesquiterpene type from Jasonia montana. Phytochemistry, 27: 3875-3877.
Ahmed, A.A., 1991. Two geraniol derivatives from Jasonia montana. Pharmazie, 46: 362-363.
Ahmed, A.A., A.A. Ali and T.J. Mabrya, 1989. Flavonoid aglycones from Jasonia montana. Phytochemistry, 28: 665-667.
El-Gizawy, H.A. and M.A. Hussein, 2015. Fatty acids profile, nutritional values, anti-diabetic and antioxidant activity of the fixed oil of Malva parviflora growing in Egypt. Int. J. Phytomed., 7: 219-230.
Hussein, M.A., 2008. Antidiabetic and antioxidant activity of Jasonia montana extract in streptozotocin-induced diabetic rats. Saudi Pharm. J., 16: 214-221.
Koheil, M.A., M.A. Hussein, S.M. Othman and A. El-Haddad, 2011. Anti-inflammatory and antioxidant activities of Moringa peregrina seeds. Free Radicals Antioxid., 1: 49-61.
Hussein, M.A. and S.M. Abdel-Gawad, 2010. Protective effect of Jasonia montana against ethinylestradiol-induced cholestasis in rats. Saudi Pharm. J., 18: 27-33.
Hussein, M.A., 2011. Anti-obesity, antiatherogenic, anti-diabetic and antioxidant activities of J. montana ethanolic formulation in obese diabetic rats fed high-fat diet. Free Radicals Antioxidants, 1: 49-62.
de Jong, W.H. and P.J.A. Born, 2008. Drug delivery and nanoparticles: Applications and hazards. Int. J. Nanomed., 3: 133-149.
Cho, K., X. Wang, S. Nie, Z.G. Chen and D.M. Shin, 2008. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 14: 1310-1316.
Ibrahim, W.M., A.H. AlOmrani and A.E.B. Yassin, 2014. Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability. Int. J. Nanomed., 9: 129-144.
Hussein, M.A., 2013. Prophylactic effect of resveratrol against ethinylestradiol-induced liver cholestasis. J. Med. Food, 16: 246-254.
Boussaada, O., S. Ammar, D. Saidana, J. Chriaa and I. Chraif et al., 2008. Chemical composition and antimicrobial activity of volatile components from capitula and aerial parts of Rhaponticum acaule DC growing wild in Tunisia. Microbiol. Res., 163: 87-95.
Finney, D.J., 1964. Statistical Method in Biological Assay. Charles Griffin Ltd., London.
Dudka, J., R. Gieroba, A. Korga, F. Burdan and W. Matysiak et al., 2012. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evidence-Based Complementary Altern. Med., Vol. 2012.
Reitman, S. and S. Frankel, 1957. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 28: 56-63.
Kind, P.R.N. and E.J. King, 1954. Estimation of plasma phosphatase by determination of hydrolysed phenol with amino-antipyrine. J. Clin. Pathol., 7: 322-326.
Buhl, S.N. and K.Y. Jackson, 1978. Optimal conditions and comparison of lactate dehydrogenase catalysis of the lactate to pyruvate and pyruvate to lactate in human serum at 25, 30 and 37 oC. Clin. Chem., 24: 828-831.
Bancroft, G.D. and A. Steven, 1983. Theory and Practice of Histological Technique. 4th Edn., Churchill Livingstone, New York, Pages: 99-112.
SPSS Inc., 2012. SPSS Statistics for Windows, Version 15.0. Chicago: SPSS Inc.,
Berthiaume, J.M. and K.B. Wallace, 2007. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc. Toxicol., 7: 178-191.
Lebrecht, D., A. Geist, U.P. Ketelsen, J. Haberstroh, B. Setzer and U.A. Walker, 2007. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br. J. Pharmacol., 151: 771-778.
Lemasters, J.J. and N. Anna-Liisa, 2007. Mitochondria in Pathogenesis. 1st Edn., Springer US, United States, Pages: 529.
Abdalla, F.H., A.M. Cardoso, L.B. Pereira, R. Schmatz and J.F. Gonçalves et al., 2013. Neuroprotective effect of quercetin in ectoenzymes and acetylcholinesterase activities in cerebral cortex synaptosomes of cadmium-exposed rats. Mol. Cell. Biochem., 381: 1-8.
Pecoraro, M., M. Del Pizzo, S. Marzocco, R. Sorrentino and M. Ciccarelli et al., 2016. Inflammatory mediators in a short-time mouse model of doxorubicin-induced cardiotoxicity. Toxicol. Appl. Pharmacol., 293: 44-52.
Wu, R., H.L. Wang, H.L. Yu, X.H. Cui, M.T. Xu, X. Xu and J.P. Gao, 2016. Doxorubicin toxicity changes myocardial energy metabolism in rats. Chem.-Biol. Interact., 244: 149-158.
Liu, X., Y. Xue, C. Liu, Q. Lou and J. Wang et al., 2013. Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis., 12: 109-115.
Scicchitano, P., M. Cameli, M. Maiello, P.A. Modesti and M.L. Muiesan et al., 2014. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics. J. Funct. Foods, 6: 11-32.
Quinn, J.F., R. Raman, R.G. Thomas, K. Yurko-Mauro and E.B. Nelson et al., 2010. Docosahexaenoic acid supplementation and cognitive decline in alzheimer disease. JAMA, Vol. 304.
Saw, C.L., Y. Huang and A.N. Kong, 2010. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: Docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol., 79: 421-430.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
